
AbbVie and OSE Immunotherapeutics Collaborate to Advance Novel Monoclonal Antibody for Chronic Inflammation Treatment
AbbVie Inc. (NYSE: ABBV) and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, have announced a strategic partnership aimed at developing OSE-230, a monoclonal antibody designed to…












